CNS

C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024

Retrieved on: 
Monday, April 8, 2024
Brain, RAF, Survival, NSCLC, Disease, Colorectal cancer, Cetuximab, Patient, CNS, The central science, Lung cancer, BRAF, AACR, Therapy, CRC, Poster, CCCC, Mutation, Vaccine

CFT1946 is an orally bioavailable BiDAC™ degrader that selectively degrades the BRAF V600X mutant protein and prevents RAF dimer-mediated resistance.

Key Points: 
  • CFT1946 is an orally bioavailable BiDAC™ degrader that selectively degrades the BRAF V600X mutant protein and prevents RAF dimer-mediated resistance.
  • Further, in a significant number of patients with BRAF V600X melanoma and NSCLC, the disease metastasizes to the brain.
  • Promising activity of CFT1946 as a single agent in a broad range of BRAF V600X preclinical models, including models of BRAFi resistance.
  • Details of the poster are as follows:
    Title: CFT1946, a potent, selective BRAF V600X mutant-specific degrader demonstrates superior activity as a single agent to clinically approved BRAF inhibitors and standard of care combinations in preclinical models of BRAF V600X melanoma, CRC, NSCLC, and brain metastasis

Robbins LLP Reminds Investors to Seek Counsel in the Class Action Against Anavex Life Sciences Corporation (AVXL)

Retrieved on: 
Friday, April 5, 2024
Rett, Excellence, Central nervous system, Patient, SAN, CNS, Rett syndrome, Complaint, News, LLP, Person, Pharmaceutical industry

SAN DIEGO, April 05, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons who purchased or otherwise acquired Anavex Life Sciences Corporation (NASDAQ: AVXL) stock between February 1, 2022 and January 1,2024.

Key Points: 
  • SAN DIEGO, April 05, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons who purchased or otherwise acquired Anavex Life Sciences Corporation (NASDAQ: AVXL) stock between February 1, 2022 and January 1,2024.
  • For more information, submit a form , email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.
  • Anavex sponsored the “Excellence” Phase II/Phase III study to investigate blarcamesine as a treatment for pediatric Rett syndrome patients.
  • What Now: You may be eligible to participate in the class action against Anavex Life Sciences Corporation.

Praxis Precision Medicines to Participate in Upcoming April Conferences

Retrieved on: 
Friday, April 5, 2024
Praxis, Central nervous system, Webcast, CNS, Conference, Piper Sandler Companies

BOSTON, April 05, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will take part in upcoming conferences in April.

Key Points: 
  • BOSTON, April 05, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will take part in upcoming conferences in April.
  • Praxis management will participate in a fireside chat at the Needham 23rd Annual Healthcare Conference, taking place virtually on April 8, 2024 at 8:00a.m EDT.
  • A replay of the webcast will be available on Praxis’ website for 90 days following the event.
  • Management will also participate in the Piper Sandler Spring Biopharma Symposium, taking place in Boston, MA on April 16-17, 2024.

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Friday, April 5, 2024
Central nervous system, AAV, CNS, Employment, Compensated emancipation

DALLAS, April 05, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system (CNS), today announced that, on April 1, 2024, the Compensation Committee of Taysha's Board of Directors granted three new employees, in the aggregate, options to purchase 140,000 shares of the Company's common stock in connection with their employment.

Key Points: 
  • DALLAS, April 05, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system (CNS), today announced that, on April 1, 2024, the Compensation Committee of Taysha's Board of Directors granted three new employees, in the aggregate, options to purchase 140,000 shares of the Company's common stock in connection with their employment.
  • The stock options were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The stock options have an exercise price of $2.84 per share, which is equal to the closing price of Taysha's common stock on the date of grant.
  • Vesting of the stock option is subject to such employee's continued service to Taysha on each vesting date.

AVXL INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Anavex Life Sciences Corp. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Retrieved on: 
Thursday, April 4, 2024
Central nervous system, Patient, CNS, Research, Neurodevelopmental disorder, News, Avatar, Rett syndrome, Complaint, Fraud, Excellence, FDA, Central nervous system disease, Court, Person, Pharmaceutical industry

Anavex has sponsored several research studies concerning blarcamesine’s suitability to treat various CNS disorders.

Key Points: 
  • Anavex has sponsored several research studies concerning blarcamesine’s suitability to treat various CNS disorders.
  • or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660.
  • If you suffered a loss in Anavex you have until May 13, 2024, to request that the Court appoint you as lead plaintiff.
  • Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Tuesday, April 2, 2024
Central nervous system, CNS, Employment, Compensated emancipation

The stock options and restricted stock units were granted as inducements material to the employee’s entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • The stock options and restricted stock units were granted as inducements material to the employee’s entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The 2024 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Praxis, or following a bona fide period of non-employment, as an inducement material to such individuals’ entering into employment with Praxis, pursuant to Nasdaq Listing Rule 5635(c)(4).
  • The options have an exercise price of $58.60 per share, which is equal to the closing price of Praxis’ common stock on the Nasdaq Global Select Market on the date of grant.
  • The restricted stock units will vest in four equal annual installments, subject to the employee’s continued employment with Praxis on each vesting date.

Cerevance to Participate at the 23rd Annual Needham Virtual Health Care Conference

Retrieved on: 
Tuesday, April 2, 2024
Central nervous system, Therapy, CNS, Conference

BOSTON, April 02, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system (CNS) diseases, today announced participation at the upcoming 23rd Annual Needham Virtual Health Care Conference.

Key Points: 
  • BOSTON, April 02, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system (CNS) diseases, today announced participation at the upcoming 23rd Annual Needham Virtual Health Care Conference.
  • The event takes place from April 8-11, 2024.
  • Company management will also host one-on-one meetings during the conference.

ANAVEX LIFE SCIENCES CORPORATION (NASDAQ: AVXL) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Anavex Life Sciences Corporation

Retrieved on: 
Monday, April 1, 2024
Central nervous system, District court, Patient, CNS, Research, Neurodevelopmental disorder, News, Avatar, Rett syndrome, Complaint, Action Replay, Excellence, FDA, Central nervous system disease, Court, Advertising

NEW YORK, April 01, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP:

Key Points: 
  • NEW YORK, April 01, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP:
    Do you, or did you, own shares of Anavex Life Sciences Corporation (NASDAQ: AVXL)?
  • If you wish to serve as lead plaintiff, you must move the Court no later than May 13, 2024.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder

Retrieved on: 
Monday, April 1, 2024
Central nervous system, Binge eating disorder, Patient, CNS, BED, Therapy, Safety, Pharmaceutical industry

NEW YORK, April 01, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, announced the initiation of the ENGAGE Phase 3 trial of solriamfetol, an investigational treatment for binge eating disorder (BED) in adults.

Key Points: 
  • NEW YORK, April 01, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, announced the initiation of the ENGAGE Phase 3 trial of solriamfetol, an investigational treatment for binge eating disorder (BED) in adults.
  • ENGAGE (Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol) is a Phase 3, randomized, double-blind, placebo-controlled, multicenter trial to assess the efficacy and safety of solriamfetol for the treatment of BED in adults.
  • Approximately 450 patients will be randomized in a 1:1:1 ratio to receive solriamfetol (150 or 300 mg) or placebo for 12 weeks.
  • The first patient was screened in the ENGAGE trial in March 2024.

Trevena Reports Fourth Quarter 2023 Results and Provides Corporate Update

Retrieved on: 
Monday, April 1, 2024
Blood pressure, EEG, Epilepsy, Bradycardia, Trevena, Rat, Neuropathic pain, Seizure, Central nervous system, Patient, CNS, TMS, Hospital, Sale, Chronic pain, NIH, IND, POC, Safety, Astrocyte, Status epilepticus, Neuroinflammation, Pharmaceutical industry

CHESTERBROOK, Pa., April 01, 2024 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today reported its financial results for the fourth quarter ended December 31, 2023 and provided an overview of its recent operational highlights.

Key Points: 
  • Given performance to date, we are reducing commercial support and reviewing alternatives for OLINVYK to preserve capital,” said Carrie Bourdow, President and CEO of Trevena.
  • OLINVYK will remain available for purchase by customers, who can continue to order the product through their normal channels.
  • In a review of safety and tolerability across both studies, TRV045 was well tolerated with results generally consistent with prior first-in-human studies.
  • For the fourth quarter of 2023, the Company reported a net loss attributable to common stockholders of $16.5 million, or $1.06 per share, compared to $7.0 million, or $0.73 per share in the fourth quarter of 2022.